In Vivo Systems: Animal Models of Neurodegeneration

作者: X. Zhang , M.G. Paule

DOI: 10.1016/B978-0-08-046884-6.01324-5

关键词:

摘要: Neurotoxicants may act on critical mechanisms in the most vital processes of nervous system and lead to damage at molecular, cellular, anatomical, physiological, behavioral levels. Since neurotoxicant-induced changes can be comparable those observed many neurological disorders, specific neurotoxicants related compounds have increasingly been used study cellular physiology pathophysiology associated with them. Most diseases unknown etiologies present complicated pathological profiles. Disease involve neurotransmitters their receptors, signal transduction, synaptic plasticity, metabolic processes, gene expression. The utilization nonhuman animals that share characteristics a human disease effectively simplify or isolate interest offer high degree experimental control. In addition, animal models provide opportunities for investigating aspects states would not feasible patients, appropriate successfully identify new therapeutic strategies treatment diseases. The main focus this chapter is describe representative are currently being research review some recent findings basic underlying processes. These important only enhancing broadening our knowledge potential etiologies, but also developing novel more effective will benefit humans counterparts. Although we acknowledge existence several other relevant chosen here about which personal experience and/or particular interest. Specifically, consequences developmental exposure drugs ketamine remacemide as N-methyl-d-aspartate (NMDA) receptor antagonists cocaine, commonly abused central (CNS) stimulant thought primarily through dopaminergic mechanisms. To varying degrees, these agents derange normal brain development result resemble learning disabled mentally retarded. Additionally, highlight use adult Parkinson’s (PD) Alzheimer’s (AD).

参考文章(174)
Michael W. Jakowec, Giselle M. Petzinger, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comparative Medicine. ,vol. 54, pp. 497- 513 ,(2004)
Fiona Thomson, Parkinson's Disease Neuron. ,vol. 39, pp. 889- 909 ,(2003) , 10.1016/S0896-6273(03)00568-3
Merle G. Paule, Philip J. Bushnell, Jacques P.J. Maurissen, Galen R. Wenger, Jerry J. Buccafusco, John J. Chelonis, Rebecca Elliott, Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicology and Teratology. ,vol. 20, pp. 493- 502 ,(1998) , 10.1016/S0892-0362(98)00013-0
Emily P. Huang, Charles F. Stevens, The matter of mind: molecular control of memory. Essays in Biochemistry. ,vol. 33, pp. 165- 178 ,(1998) , 10.1042/BSE0330165
E.J Popke, R Patton, G.D Newport, L.G Rushing, C.M Fogle, R.R Allen, E.C Pearson, T.G Hammond, M.G Paule, Assessing the potential toxicity of MK-801 and remacemide: chronic exposure in juvenile rhesus monkeys. Neurotoxicology and Teratology. ,vol. 24, pp. 193- 207 ,(2002) , 10.1016/S0892-0362(02)00206-4
Olaf Riess, R. Krüger, Parkinson’s disease — a multifactorial neurodegenerative disorder Journal of Neural Transmission-supplement. ,vol. 56, pp. 113- 125 ,(1999) , 10.1007/978-3-7091-6360-3_6
E. C. Hirsch, Animal models in neurodegenerative diseases Journal of Neural Transmission. Supplementa. pp. 87- 90 ,(2007) , 10.1007/978-3-211-73574-9_11
Merle, G. Paule, Chronic drug exposures during development in nonhuman primates: models of brain dysfunction in humans Frontiers in Bioscience. ,vol. 10, pp. 2240- 2249 ,(2005) , 10.2741/1693
Merle G. Paule, Exposure to Drugs of Abuse: Alterations in Nonhuman Primate Development as Models of Adverse Consequences Primate Models of Children's Health and Developmental Disabilities. pp. 301- 323 ,(2008) , 10.1016/B978-012373743-4.50014-X